Cellectis SA (CLLS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.53 (+4.79%), Market cap $0.36B, 52-week low–high $1.33 ~ $5.35.
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatm
Financial statements, price targets, institutional (13F) holdings and related news for Cellectis SA are updated in real time on BlackAll Trade.
Cellectis SA trades at $1.53 (+4.79%). Real-time quotes and charts are available on BlackAll Trade.
Cellectis SA has a market cap of about $0.36B.
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of i